Related references
Note: Only part of the references are listed.EFFECTS OF AMG 145, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST PCSK9, ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN SUBJECTS TAKING STATINS: A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING MULTIPLE-DOSE STUDY
Clapton Dias et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
James M. McKenney et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
Evan A. Stein et al.
LANCET (2012)
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Evan A. Stein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Effect of Lipid-Lowering Treatment on Natural History of Heterozygous Familial Hypercholesterolemia in Past Three Decades
Avishay Elis et al.
AMERICAN JOURNAL OF CARDIOLOGY (2011)
Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
Fatima Akdim et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: A large cross-sectional study in The Netherlands
A. H. Pijlman et al.
ATHEROSCLEROSIS (2010)
Lipoprotein(a) as a cardiovascular risk factor: current status
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2010)
PCSK9: a convertase that coordinates LDL catabolism
Jay D. Horton et al.
JOURNAL OF LIPID RESEARCH (2009)
Update and analysis of the University College London Low Density Lipoprotein receptor familial hypercholesterolemia database
S. E. A. Leigh et al.
ANNALS OF HUMAN GENETICS (2008)
Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study
Andrew Neil et al.
EUROPEAN HEART JOURNAL (2008)
Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia
Frederick F. Samaha et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2008)
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study
Jorie Versmissen et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterotemia
Evan A. Stein et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2007)
First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay - Lp(a) SRM 2B
F Dati et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2004)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
The College of American Pathologists laboratory accreditation program
A Rabinovitch
ACCREDITATION AND QUALITY ASSURANCE (2002)
The Friedewald formula underestimates LDL cholesterol at low concentrations
H Scharnagl et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2001)